Adjuvant chemotherapy for stage III colon cancer in the oldest old: Results beyond clinical guidelines

Cancer

Volumn 119, Issue 2, 2013, Pages 395-403

  Abraham, Anasooya ^a   Habermann, Elizabeth B ^a   Rothenberger, David A ^a   Kwaan, Mary ^a   Weinberg, Armin D ^b   Parsons, Helen M ^a   Gupta, Pankaj ^c,d   Al Refaie, Waddah B ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Minneapolis Veterans Affairs Health Care System   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

age disparities; chemotherapy; colon cancer; elderly cancer care

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLON ADENOCARCINOMA; COLON CANCER; COLON RESECTION; COMORBIDITY; DISEASE ASSOCIATION; ELDERLY CARE; FEMALE; FUNCTIONAL STATUS; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; TREATMENT INDICATION; UNITED STATES; VERY ELDERLY;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; PROPENSITY SCORE; RETROSPECTIVE STUDIES;

EID: 84872060348     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27755     Document Type: Article

References (25)

1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Fast Stats: An Interactive Tool for Access to SEER Cancer Statistics. http://seer.cancer.gov/faststats. Accessed December 20, 2010.
2. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
3. Bullard K, Rothenberger DA,. Colon, rectum and anus. In:, Brunicardi F, ed. Schwartz's Principles of Surgery. 9th ed. New York: McGraw-Hill Company; 2010: 1013-1072.
4. Etzioni DA, Beart RW Jr, Madoff RD, Ault GT,. Impact of the aging population on the demand for colorectal procedures. Dis Colon Rectum. 2009; 52: 583-590; discussion 590-591.
5. Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD,. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010; 100 (suppl 1): S105-S112.
6. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/, 5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
7. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091-1097.
8. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 1797-1806.
9. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W,. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006; 98: 610-619.
10. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI,. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002; 136: 349-357.
11. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010; 303: 1037-1045.
12. California Department of Public Health. California Cancer Registry. http://www.ccrcal.org/. Accessed on April 10, 2012.
13. Schrag D, Cramer LD, Bach PB, Begg CB,. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93: 850-857.
14. Jessup JM, Stewart A, Greene FL, Minsky BD,. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005; 294: 2703-2711.
15. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204.
16. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007; 25: 2205-2211.
17. Choi J, Kong K, Mozaffar T, Holcombe RF,. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs. 2006; 17: 103-105.
18. Moore M, Gibbs P,. Adjuvant chemotherapy use among older patients with stage III colon cancer. JAMA. 2010; 303: 2353; author reply 2353-2354.
19. Tan KY, Konishi F, Suzuki K,. The evidence for adjuvant treatment of elderly patients (age > or = 70) with stage III colon cancer is inconclusive. Surg Today. 2010; 40: 385-387.
20. Nass SJ, Balogh E, Mendelsohn J,. A National Cancer Clinical Trials Network: recommendations from the Institute of Medicine. Am J Ther. 2011; 18: 382-391.
21. Al-Refaie WB, Parsons HM, Henderson WG, et al. Major cancer surgery in the elderly: Results from the American College of Surgeons National Surgical Quality Improvement Program. Ann Surg. 2010; 251: 311-318.
22. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003; 21: 1293-1300.
23. Kunitake H, Zingmond DS, Ryoo J, Ko CY,. Caring for octogenarian and nonagenarian patients with colorectal cancer: what should our standards and expectations be? Dis Colon Rectum. 2010; 53: 735-743.
24. Davidoff AJ, Tang M, Seal B, Edelman MJ,. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28: 2191-2197.
25. US Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 627-637.